Ocular Discomfort

Pipeline Programs

Companies

Clinical Trials

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

DompéItaly - L'Aquila

2 programs

rhNGFPhase 21 trial

Lubricin 20µg/mlN/A1 trial

Active Trials

NCT03031327Completed30Est. Aug 2017

NCT03035864Completed180Est. Sep 2017

Bausch + LombNJ - Bridgewater

1 program

Bausch & Lomb Multi-Purpose SolutionN/A

Bausch HealthQUEBEC, Quebec, Canada

1 program

Bausch & Lomb Multi-Purpose SolutionN/A1 trial

Active Trials

NCT01024751Completed312Est. Feb 2010

VisufarmaNetherlands - Amsterdam

1 program

VisuXL®N/A1 trial

Active Trials

NCT03844737Completed20Est. Dec 2018

Trial Timeline

Clinical trial activity over time

2021

2022

2023

2024

2025

2026

DompérhNGF

VisufarmaVisuXL®

DompéLubricin 20µg/ml

Bausch HealthBausch & Lomb Multi-Purpose Solution

Clinical Trials (4)

Total enrollment: 542 patients across 4 trials

NCT03035864 DompérhNGF

A 8 Weeks Study to Evaluate Efficacy & Safety of rhNGF vs Vehicle in Patients After Cataract and Refractive Surgery

Start: Jan 2017Est. completion: Sep 2017180 patients

Phase 2Completed

NCT03844737 VisufarmaVisuXL®

Evaluation of the VisuXL® Performance on Ocular Surface Discomfort

Start: Oct 2018Est. completion: Dec 201820 patients

N/ACompleted

NCT03031327 DompéLubricin 20µg/ml

Safety and Efficacy of 2 Concentrations of Lubricin vs Sodium Hyaluronate in Ocular Discomfort After Refractive Surgery.

Start: Jun 2017Est. completion: Aug 201730 patients

N/ACompleted

NCT01024751 Bausch HealthBausch & Lomb Multi-Purpose Solution

A Study to Evaluate the Clinical Performance of a Novel Multipurpose Solution

Start: Nov 2009Est. completion: Feb 2010312 patients

N/ACompleted

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.